Background

NAD+ levels exhibit robust circadian oscillations in young tissues, driven by the rhythmic expression of NAMPT (the rate-limiting NAD+ biosynthetic enzyme) under CLOCK:BMAL1 control. With aging, both mean NAD+ levels and their circadian amplitude decline. Independently, autophagy — particularly selective mitophagy and aggrephagy — loses its circadian gating, shifting from a tightly timed nocturnal process to a constitutive low-level activity that fails to clear damaged organelles effectively.

The Hypothesis

I propose that the loss of NAD+ circadian amplitude (not merely the decline in mean NAD+ levels) is the primary causal driver of age-related autophagy desynchronization, and that this occurs through a specific molecular mechanism:

1. In youth: Peak nocturnal NAD+ activates SIRT1, which deacetylates TFEB (Transcription Factor EB) at K116 and K426, promoting its nuclear translocation specifically during the rest phase. This creates a burst of lysosomal biogenesis and selective autophagy genes (LAMP1, SQSTM1/p62, BNIP3L/NIX, OPTN) timed to the fasting/rest period.

2. With aging: Flattened NAD+ oscillations mean SIRT1 activity never reaches the threshold required for efficient TFEB deacetylation. TFEB remains hyperacetylated and cytoplasmic during what should be its nuclear phase. The result: autophagy genes are expressed at a low, arrhythmic baseline — enough to prevent acute proteotoxic crisis, but insufficient for the periodic deep clearance that maintains cellular homeostasis.

3. The desynchronization cascade: Without timed autophagic clearance, damaged mitochondria accumulate during the active phase but are not cleared during rest. This generates a chronic low-grade ROS signal that further suppresses NAMPT expression (via NF-κB-mediated CLOCK:BMAL1 disruption), creating a feed-forward loop: flattened NAD+ → poor autophagy timing → mitochondrial damage → more NAD+ flattening.

Key Prediction

Timed NMN administration (delivered 2-4 hours before the rest phase onset to reconstitute the NAD+ peak) should restore SIRT1-mediated TFEB nuclear cycling and re-establish circadian autophagy gating, whereas the same dose given at random times or continuously will raise mean NAD+ but fail to restore autophagy rhythms.

Testable Experimental Design

Model: 24-month-old C57BL/6J mice vs. 4-month-old controls

Groups (n=15/group):

• Young vehicle
• Aged vehicle
• Aged + NMN 300 mg/kg timed (ZT10, 2h before lights-on/rest)
• Aged + NMN 300 mg/kg random timing
• Aged + NMN 300 mg/kg continuous (in drinking water)

Primary endpoints (8 weeks):

1. Hepatic NAD+ oscillation amplitude (LC-MS every 4h over 24h)
2. TFEB nuclear/cytoplasmic ratio by fractionation at ZT0, ZT6, ZT12, ZT18
3. SIRT1-TFEB co-immunoprecipitation and TFEB acetylation status (K116/K426)
4. Circadian expression of autophagy genes (Sqstm1, Bnip3l, Optn, Lamp1) by RT-qPCR
5. Mitophagy flux: mt-Keima ratio (acidic/neutral) at ZT0 vs ZT12

Secondary endpoints:

• Epigenetic clock (Horvath pan-tissue) at baseline and 8 weeks
• Grip strength, rotarod, VO2max
• Hepatic lipofuscin and 8-OHdG (oxidative damage markers)

Falsification Criteria

The hypothesis is falsified if:

• Timed NMN fails to restore TFEB nuclear cycling (>2-fold amplitude difference vs. random timing)
• SIRT1 inhibition (EX-527) during the NAD+ peak does not abolish TFEB nuclear translocation
• Continuous NMN produces equivalent autophagy rhythm restoration as timed NMN
• Young NAMPT-KO mice with flattened NAD+ oscillations show normal autophagy rhythms

Clinical Implications

If confirmed, this reframes the entire NMN/NR supplementation field: chronotherapy matters more than dose. Current human trials administer NMN at arbitrary times; our hypothesis predicts that only evening-timed dosing (before the human rest phase) would meaningfully restore autophagic clearance. This could explain the inconsistent results of NAD+ precursor trials to date — they may be raising mean NAD+ without reconstituting the oscillation that drives the biological effect.

Relevance to Autoimmune Aging

In rheumatic diseases, glucocorticoid therapy disrupts circadian cortisol rhythms. Dexamethasone suppresses NAMPT expression in a dose-dependent manner (PMID 25681385), potentially flattening NAD+ oscillations pharmacologically and accelerating the autophagy desynchronization described here. This may represent an underrecognized mechanism of accelerated aging in autoimmune patients on chronic steroids — and a rationale for timed NAD+ precursor co-administration.

References

• Nakahata et al. (2009) SIRT1-NAMPT circadian NAD+ salvage. Science 324(5927):654-7. PMID 19286518
• Settembre et al. (2011) TFEB links autophagy to lysosomal biogenesis. Science 332(6036):1429-33. PMID 21617040
• Ma et al. (2020) Circadian autophagy rhythm. Autophagy 16(12):2113-2128. PMID 31931660
• Mills et al. (2016) Long-term NMN administration in mice. Cell Metab 24(6):795-806. PMID 28068222
• Levine et al. (2018) Epigenetic age and aging-related outcomes. Aging 10(4):573-591. PMID 29676998